We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary tools and understanding of the target allow us to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth. As a result of PP2A’s central role in the regulation of protein phosphorylation, Rappta’s PP2A-reactivating technologies have platform potential in human therapeutic use.
The hyperphosphorylation of proteins because of the activation of kinases and inactivation of phosphatases is a hallmark of many diseases ranging from neurodegeneration to cancer.
PP2A is a key tumor suppressor and a critical enzyme regulating protein de-phosphorylation and tumor growth, but it has to date been very difficult to target pharmaceutically.
We have assembled a strong scientific, medchem, management, and commercial team based in Finland and the US. Our scientific team has published seminal papers on the structural, functional, and biological mechanisms of PP2A inactivation in human cancer.
Rappta Therapeutics announces today the appointment of Sunjeet Sawhney as Chief Executive Officer (CEO) with immediate effect. Rappta’s Co-founder and Founding CEO Mikko Mannerkoski will move to be Chief Financial Officer (CFO) as planned.